Pfizer Inc. Bone Drug, Fablyn Reduces Breast Cancer Risk in Older Women

Bloomberg -- Pfizer Inc.’s Fablyn, the bone drug that failed to win U.S. approval amid safety questions, reduced the risk of breast cancer and fractures in postmenopausal women with osteoporosis, a company-sponsored study found.